Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) in their CSF despite completion of their first treatment (first-line treatment).

serum bilirubin level
aptt
nivolumab
platelet transfusion
blood transfusion
  • 0 views
  • 19 Feb, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

metastasis
metastatic melanoma
ipilimumab
adjuvant therapy
brain metastases
  • 0 views
  • 19 Feb, 2024
Video-assisted Thoracoscopic Thymectomy Versus Subxiphoid Procedure

Surgerys used in thymectomy for myasthenia gravis and anterior mediastinal tumours have become much less invasive in recent years. In our study, the surgical technique which resected the thymus below the xiphoid process and the technique which was regarded as conventional video- assisted thoracoscopic surgery (VATS) thymectomy was compared.

  • 0 views
  • 19 Feb, 2024
Fuzheng Yiliu-1010

Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population of Fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.

  • 0 views
  • 19 Feb, 2024
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Approximately 100 adult participants with locally advanced, recurrent, or metastatic solid tumors will be enrolled.

solid neoplasm
measurable disease
ejection fraction
  • 0 views
  • 19 Feb, 2024
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

To assess anti-tumor activity of avelumab in combination with axitinib in patients with unresectable/metastatic GIST after progression on second or third line treatment (after failure on at least of imatinib and sunitinib) in terms of progression-free survival (PFS)

myocardial infarction
avelumab
diastolic blood pressure
metastasis
metastatic gastrointestinal stromal tumor
  • 0 views
  • 19 Feb, 2024
MTD Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors

The objectives of this study are: Part 1: To assess the MTD, safety and efficacy of each NYH817G and NYH100P in monotherapy in patients with advanced solid tumors who have failed approved standard therapies. To assess the PK properties and the preliminary effectiveness of monotherapy of NYH817G and NYH100P.

  • 0 views
  • 19 Feb, 2024
A Study to Evaluate the Tolerance Efficacy and Pharmacokinetics of TQB3558 Tablets

This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients with advanced solid tumors .The study is divided into phase Ia and phase Ib. …

  • 0 views
  • 19 Feb, 2024
First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) and of M6223 combined with bintrafusp alfa (Part 1B) in participants with metastatic or locally advanced solid unresectable tumors.

  • 0 views
  • 19 Feb, 2024